This week, we have a conversation with Peter G. Milner, founder and director of Renexxion, about GI motility disorders.
Renexxion
Renexxion, Inc. is a privately held US-headquartered clinical-stage biopharmaceutical company, with a subsidiary in Ireland, committed to developing new therapies for patients with gastrointestinal disorders.
Renexxion’s lead program is naronapride, a late-stage drug candidate being developed for multiple unmet indications in the upper and lower GI tract.
Dr. Falk Pharma GmbH, a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion recently announced positive results from MOVE-IT, a global phase 2b, randomised placebo-controlled trial evaluating the efficacy, safety, and tolerability of naronapride in adults with gastroparesis.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
Podden och tillhörande omslagsbild på den här sidan tillhör
Jim Cornall. Innehållet i podden är skapat av Jim Cornall och inte av,
eller tillsammans med, Poddtoppen.
